Current & Upcoming Clinical Trials
AbbVie: Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men.
This study will look at the effects of testosterone replacement therapy (TRT) on major adverse cardiovascular events (MACE).
Gilead: A Phase 1B randomized, double-blinded, placebo-controlled, multi-cohort study of the safety, pharmacokinetics, and antiviral activity of GS-6207 administered subcutaneously in HIV-1-infected subjects.
This study is looking at the safety and effects of a new long-acting injectable therapy called a “capsid inhibitor” for treatment of HIV.
Trogarzo Study: A Phase 3 study of the safety of Trogarzo™ administered as an undiluted “IV Push” over a reduced interval in clinically-stable HIV-1 infected Trogarzo™ experienced patients.
Upcoming trials with novel antiretroviral Islatravir (Merck MK-8591) for treatment naïve and treatment experienced HIV-1 patients.
Upcoming trials with Capsid Inhibitor (Gilead).
Interested in participating in a clinical trial?
Contact us to see if you qualify as a candidate for one of our studies!